Zur Hauptnavigation wechseln Zur Suche wechseln Zum Hauptinhalt wechseln

Variation of the baseline characteristics and treatment parameters over time: An analysis of 15 years of growth hormone replacement in adults in the German KIMS database

I. Kreitschmann-Andermahr*, S. Siegel, F. Francis, M. Buchfelder, H. J. Schneider, P. H. Kann, H. Wallaschofski, M. Koltowska-Häggström, G. Brabant

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

The purpose of this study is to examine potential implications of changes in the approach to adult growth hormone (GH) replacement (GHR) over the last 15 years. Therefore, we analysed the German KIMS database as one of the largest single country pharmacoepidemiological databases on adult GH deficiency (GHD). Based on the date of their first GH application patients were assigned to three intervals (1995-1999, 2000-2004, 2005-2009). A multivariate analysis of variance with interval and sex as independent variables was conducted. Differences were analysed with respect to IGF-I standard deviation score (SDS), quality of life, latency between GHD diagnosis and first GH dose, body mass index, waist-hip ratio, lipid profile, and GH dose. All analyses were conducted at baseline, 1 year, and 3 years of GHR. We detected significant associations between time interval and patient characteristics at baseline and with treatment effects. Recently, patients with less severe GHD (mean IGF-I SDS: -2.1, -1.6, -1.0 in the 1st, 2nd and 3rd interval; p = 0.000) are treated with lower GH starting doses (mean 0.30, 0.19, 0.21 mg/day in the 1st, 2nd and 3rd interval; p = 0.000). In the first time interval, IGF-I SDS was not normalized in females after 3 years of GHR. The results of our analysis demonstrate prominent changes in patient characteristics and handling of GHR. They highlight that approach to therapy and patient inclusion criteria change over time and may represent an important confounder for any analysis in epidemiological surveillance surveys.

OriginalspracheEnglisch
ZeitschriftPituitary
Jahrgang15
Ausgabenummer1 SUPPL.
ISSN1386-341X
DOIs
PublikationsstatusVeröffentlicht - 01.12.2012

Fördermittel

Acknowledgments We would like to express our thanks to the participants of KIMS in Germany who provided the data on their patients and to the colleagues working at KIGS/KIMS/Acrostudy Medical Outcomes in Berlin and Stockholm. Without their commitment, support and daily hard work the KIMS database would not exist. (Prof. Dr. C. Schöfl, University of Erlangen; Prof. Dr. M. Weber, University of Mainz; Prof. Dr. C. Kasperk, Prof. Dr. P. Nawroth, University of Heidelberg; Dr. C. Auernhammer, University of Munich; Prof. Dr. K. Mann, University of Essen; Dr. J. Krug, Clinical Center St. Georg Leipzig; Prof. Dr. R. F. Hampel, University of Rostock; Prof. Dr. U. Tuschy, University of Erfurt; Prof. Dr. N. Stahnke, Endokrinologikum Hamburg; Prof. Dr. H.-U. Häring, University of Tübingen; Prof. Dr. D. Klingmüller, University of Bonn; Prof. Dr. P. Ball, Lübeck; Dr. J. Ittner, Augsburg; Dr. C. Ker-ber, HELIOS Schwerin; Dr. R. Gellner, University of Münster; Prof. Dr. K.-J. Gräf, Endokrinologikum Berlin; Prof. Dr. G. Stalla, Max-Planck-Institute Munich; Prof. Dr. F.-U. Beil, UKE Hamburg; Dr. J. Santen, Dr. R. Engelbach, Frankfurt; Dr. M. Faust, University of Cologne; Dr. K. Reschke, University of Magdeburg; Prof. Dr. P. Weisweiler, Munich; Dr. M. Droste, Oldenburg; Dr. U. Deuß, Cologne; Dr. C. Terkamp, MHH Hanover; Dr. K. Ventzke, Bremen; Prof. Dr. H.M. Schulte, Endokrinologikum Hamburg; Dr. J. Schopohl, University of Munich; Dr. C. Jaursch-Hanke, DKD GFF Wiesbaden; Dr. M. Gruber, University of Dresden; Prof. Dr. M. Stumvoll, University of Leipzig; Prof. Dr. O.A. Müller, ‘‘RotKreuz’’ Hospital Munich; Prof. Dr. H. Stracke, University of Giessen; Dr. W. Faßb-ender, Hospital zum Hl. Geist Kempen; Dr. E. Jochum, Krankenhaus der Barmherzigen Brüder, Trier; Dr. F. Demtröder, Städtisches Klinikum Dortmund gGmbH; Prof. Dr. T. H. Schürmeyer, Mutterhaus der Borromäerinnen Trier; Dr. F. Schröder, Brandenburg; Prof. Dr. K. Badenhoop, University of Frankfurt; Prof. Dr. W. Karges, University of Aachen; Dr. S. Levasseur, Aachen; Prof. Dr. J. Seufert, University of Freiburg; Prof. Dr. J. Hensen, Klinikum Nordstadt Hanover; Prof. Dr. U. Bogner, Berlin; Dr. R. Gutekunst, Lübeck; Prof. Dr. P. Kann, University of Marburg; Dr. U. Schröder, Endokr-inologikum Hanover; Dr. U. Plöckinger, University of Berlin; Dr. K. Wiener, Cottbus; Dr. J. Feldkamp, Bielefeld; Dr. A. Hoffmann, Cologne; Dr. J. Wildbrett, Dresden; Dr. H. Dirks, Bremen; Prof. Dr. U. Schneyer, University of Halle; Dr. M. Wolf, Hospital Bietigheim-Bissingen; Dr. V. Hector, Hamburg; Dr. A. Figge, University of Bochum; Prof. Dr. A. Hübner, University of Dresden; Dr. H.J. Kröhne, Jena; Dr. C. Weber, Halberstadt; Dr. W. Omran, Mainz; Dr. B. Gerbert, Endokrinologikum Dresden; Dr. B. Stamm, Saarbrücken; Dr. S. Müller, Karslruhe; Dr. C.-D. Pflaum, Augsburg) KIMS is supported by Pfizer. Board. Michael Buchfelder is also a member of the Strategic Advisory Board of KIMS. Maria Koltowska-Häggström is a permanent employee of Pfizer Inc. Ilonka Kreitschmann-Andermahr, Georg Brabant, Michael Buchfelder, Peter Kann, Harald Schneider and Henri Wallaschofski have received research grants from Pfizer for research unrelated to the contents of this manuscript.

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

  1. SDG 3 – Gesundheit und Wohlergehen
    SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

  • Forschungsschwerpunkt: Gehirn, Hormone, Verhalten - Center for Brain, Behavior and Metabolism (CBBM)

Fingerprint

Untersuchen Sie die Forschungsthemen von „Variation of the baseline characteristics and treatment parameters over time: An analysis of 15 years of growth hormone replacement in adults in the German KIMS database“. Zusammen bilden sie einen einzigartigen Fingerprint.

Zitieren